Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents.

[1]  T. Henry,et al.  Early Medication Nonadherence After Acute Myocardial Infarction: Insights into Actionable Opportunities From the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. , 2015, Circulation. Cardiovascular quality and outcomes.

[2]  G. Stone,et al.  Sex‐based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONS‐AMI trial , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[3]  G. Grunwald,et al.  Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. , 2014, American heart journal.

[4]  P. Castiglioni,et al.  Gender Differences in Illness Behavior After Cardiac Surgery , 2014, Journal of cardiopulmonary rehabilitation and prevention.

[5]  E. Peterson,et al.  Sex‐Based Differences in Outcomes After Percutaneous Coronary Intervention for Acute Myocardial Infarction: A Report From TRANSLATE‐ACS , 2014, Journal of the American Heart Association.

[6]  R. Verbrugge,et al.  Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. , 2014, Journal of women's health.

[7]  Antonio Colombo,et al.  Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.

[8]  Hassan Khan,et al.  Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. , 2013, European heart journal.

[9]  Mandeep Singh,et al.  An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry. , 2013, JACC. Cardiovascular interventions.

[10]  T. Brennan,et al.  Gender and racial disparities in adherence to statin therapy: a meta-analysis. , 2013, American heart journal.

[11]  Pamala A. Pawloski,et al.  Patient Characteristics Associated with Medication Adherence , 2013, Clinical Medicine & Research.

[12]  Laura Mauri,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.

[13]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[14]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[15]  Rowena J Dolor,et al.  Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. , 2011, Journal of the American College of Cardiology.

[16]  S. Pocock,et al.  A risk score to predict bleeding in patients with acute coronary syndromes. , 2010, Journal of the American College of Cardiology.

[17]  L. Newby,et al.  Twelve-Year Follow-Up of American Women's Awareness of Cardiovascular Disease Risk and Barriers to Heart Health , 2010, Circulation. Cardiovascular quality and outcomes.

[18]  Inger Ekman,et al.  Adherence to medication according to sex and age in the CHARM programme , 2009, European journal of heart failure.

[19]  K. Alexander,et al.  Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). , 2009, The American journal of cardiology.

[20]  Fred S Apple,et al.  Universal definition of myocardial infarction. , 2007, Journal of the American College of Cardiology.

[21]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[22]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[23]  E. Antman,et al.  Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.

[24]  M. Pfeffer,et al.  Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial , 2005, The Lancet.

[25]  Z. Vered,et al.  Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? , 2004, American heart journal.

[26]  P. Schuster,et al.  Gender Differences in Cardiac Rehabilitation Patients , 1991, Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses.